255TiP AIPAC-003: A randomized, double-blind, placebo-controlled phase III trial testing eftilagimod alpha (soluble LAG-3) in HER2-neg/low metastatic breast cancer patients receiving paclitaxel, following an open-label dose optimization
| Autor: | Duhoux, F.P., Ibrahim, N.K., Papadamitriou, K., Canon, J-L., Morales, S., Sanchez-Rovira, P., Oliveira, M., Doger de Spéville, B., Houtsma, D., Beeker, A., Peguero, J., Marathe, O., Triebel, F. |
|---|---|
| Zdroj: | In ESMO Open May 2023 8(1) Supplement 4 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|